Protective effects of (-)-epigallocatechin-3-gallate against acetaminophen-induced liver injury in rats)

Yao, Hsien Tsung; Yang, Yu Chi; Chang, Chenhui; Yang, Hui; Yin, Mei

doi:10.7603/s40681-015-0015-8

Cited by 33 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…et al, 2015 ; Wu I.C. et al, 2015 ; Yao et al, 2015 ; Yin, 2015 ; Lai et al, 2017b ; Liao et al, 2017b ). A population-based retrospective cohort study was conducted using the database from the Taiwan National Health Insurance Program.…”

Section: Methodsmentioning

confidence: 99%

Metformin Use Correlates with Reduced Risk of Gallstones in Diabetic Patients: A 12-Year Follow-up Study

Liao

Chuang²,

Lai

2017

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Few studies are available on the association between gallstones and metformin use. The objective of the study was to determine whether metformin use is associated with gallstones.Methods: A population-based retrospective cohort study was conducted using the database of the Taiwan National Health Insurance Program. Subjects of newly diagnosed diabetes mellitus were included from 2002 to 2013. The metformin-exposure group was defined as ≥29 cumulative defined daily dose (DDD) of metformin use. The un-exposure group was defined as <29 cumulative DDD of metformin use. The major endpoint was a new diagnosis of gallstones during the follow-up period. A multivariable Cox proportional hazards regression model was used to evaluate the hazard ratio (HR) and 95% confidence interval (CI) of gallstones associated with metformin use.Results: After controlling for potential confounders, the adjusted HRs of gallstones were 1.11 (95%CI: 0.84–1.46) for subjects with metformin dosage of 29–180 cumulative DDD, and 0.57 (95%CI: 0.42–0.78) for subjects with metformin dosage >180 cumulative DDD, compared with the un-exposure group.Conclusion: Long-term use of metformin is associated with reduced risk of gallstones.

show abstract

Section: Methodsmentioning

confidence: 99%

Metformin Use Correlates with Reduced Risk of Gallstones in Diabetic Patients: A 12-Year Follow-up Study

Liao

Chuang²,

Lai

2017

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Treatment with antioxidative agents has been widely considered to treat oxidative stress induced damages (Amara et al, ; Chen et al, ; Guzman‐Guillen et al, ; Hsieh et al, ; Tsai et al, ; Yang et al, ; Yao et al, ; El‐Sayed el et al, ; Sahu et al, ). Coenzyme Q10 (Q10) is a powerful antioxidant used as a nutritional supplement for cancer patients undergoing chemotherapy and as treatment for heart failure, diabetes, breast cancer, and hypertension (Niklowitz et al, ; Madmani et al, ; Yeung et al, ).…”

Section: Introductionmentioning

confidence: 99%

Protective effect of Co‐enzyme Q10 On doxorubicin‐induced cardiomyopathy of rat hearts

Chen

Hou

Shibu

et al. 2016

Environmental Toxicology

View full text Add to dashboard Cite

Q10 is a powerful antioxidant often used in medical nutritional supplements for cancer treatment. This study determined whether Q10 could effectively prevent cardio-toxicity caused by doxorubicin treatment. Four week old SD rats were segregated into groups namely control, doxorubicin group (challenged with doxorubicin), Dox + Q10 group (with doxorubicin challenge and oral Q10 treatment), and Q10 group (with oral Q10 treatment). Doxorubicin groups received IP doxorubicin (2.5 mg/kg) every 3 days and Q10 groups received Q10 (10 mg/kg) every day. Three weeks of doxorubicin challenge caused significant reduction in heart weight, disarray in cardiomyocyte arrangement, elevation of collagen accumulation, enhancement of fibrosis and cell death associated proteins, and inhibition of survival proteins. However, Q10 effectively protected cardiomyocytes and ameliorated fibrosis and cell death induced by doxorubicin. Q10 is, therefore, evidently a potential drug to prevent heart damage caused by doxorubicin. © 2016 Wiley Periodicals, Inc. Environ Toxicol 32: 679-689, 2017.

show abstract

“…Thoughtfully, the anti-oxidative effects of EGCG come into action through activation of anti-oxidation protective signaling, thus reducing injury [28,29]. Similarly, other studies have shown anti-oxidative and preventive effects of EGCG on different hepatic injury animal models [30,31].…”

Section: Discussionmentioning

confidence: 95%

Epigallocatechin-3-Gallate (EGCG), An Active Constituent of Green Tea: Implications in the Prevention of Liver Injury Induced by Diethylnitrosamine (DEN) in Rats

et al. 2019

View full text Add to dashboard Cite

Liver diseases are one of the most detrimental conditions that may cause inflammation, leading to tissue damage and perturbations in functions. Several drugs are conventionally available for the treatment of such diseases, but the emergence of resistance and drug-induced liver injury remains pervasive. Hence, alternative therapeutic strategies have to be looked upon. Epigallocatechin-3-gallate (EGCG) is a naturally occurring polyphenol in green tea that has been known for its disease-curing properties. In this study, we aimed to evaluate its anti-oxidative potential and protective role against diethylnitrosamine (DEN)-induced liver injury. Four different groups of rats were used for this study. The first group received normal saline and served as the control group. The second group received DEN (50 mg/kg body wt) alone and third group received DEN plus EGCG (40 mg/kg body wt) only. The fourth group were treated with EGCG only. The liver protective effect of EGCG against DEN toxicity through monitoring the alterations in aspartate transaminase (AST), and alanine transaminase (ALT) and alkaline phosphatase (ALP) activities, serum level of pro-inflammatory mediators and anti-oxidant enzymes, histopathological alterations, measurement of cellular apoptosis, and cell cycle analysis was examined. The rats that were given DEN only had a highly significantly elevated levels of liver enzymes and pro-inflammatory cytokines, highly decreased anti-oxidative enzymes, and histological changes. In addition, a significant elevation in the percentage of apoptotic nuclei and cell cycle arrest in the sub- G1 phase was detected. EGCG acts as a hepatoprotectant on DENs by reducing the serum levels of liver functional enzymes, increasing total anti-oxidative capacity, reducing pathological changes and apoptosis, as well as causing the movement of cells from the sub G1 to S or G2/M phase of the cell cycle. In conclusion, EGCG displayed a powerful hepatoprotective additive as it considerably mitigates the liver toxicity and apoptosis induced by DEN.

show abstract

Protective effects of (-)-epigallocatechin-3-gallate against acetaminophen-induced liver injury in rats)

Cited by 33 publications

References 29 publications

Metformin Use Correlates with Reduced Risk of Gallstones in Diabetic Patients: A 12-Year Follow-up Study

Metformin Use Correlates with Reduced Risk of Gallstones in Diabetic Patients: A 12-Year Follow-up Study

Protective effect of Co‐enzyme Q10 On doxorubicin‐induced cardiomyopathy of rat hearts

Epigallocatechin-3-Gallate (EGCG), An Active Constituent of Green Tea: Implications in the Prevention of Liver Injury Induced by Diethylnitrosamine (DEN) in Rats

Contact Info

Product

Resources

About